Tramadol HydrochlorideThird Party Manufacturing in India

Tramadol hydrochloride extended-release is a once-daily formulation of the centrally acting synthetic opioid analgesic tramadol. Tramadol exerts its analgesic effect through a complementary dual mechanism of action. It acts as a weak mu-opioid receptor agonist, with the plus-enantiomer having approximately four times higher affinity for the mu receptor than the minus-enantiomer. Additionally, tramadol inhibits the reuptake of both norepinephrine and serotonin in the central nervous system, activating descending inhibitory pathways that modulate pain transmission at the spinal and supraspinal levels.

The prodrug nature of tramadol is clinically important. It undergoes O-demethylation via the CYP2D6 isoenzyme to form O-desmethyltramadol (M1), which has 200 to 300 times greater affinity for mu-opioid receptors than the parent compound and is primarily responsible for the opioid-mediated analgesic effect. The M1 metabolite also has a longer terminal half-life than tramadol itself, contributing to sustained analgesic activity. The extended-release formulation employs a controlled-release matrix technology that allows gradual drug release over 24 hours, producing stable plasma concentrations throughout the dosing interval.

This extended-release profile minimizes the peak-to-trough fluctuations in drug concentration that occur with immediate-release formulations, providing consistent around-the-clock pain relief with reduced breakthrough pain episodes. The formulation also lowers the maximum plasma concentration compared to immediate-release formulations, which may reduce the incidence of peak-related adverse effects such as nausea, dizziness, and sedation while maintaining therapeutic efficacy.

Therapeutic Uses

Tramadol hydrochloride extended-release tablets USP 100 mg are indicated for the management of moderate to moderately severe chronic pain in adults requiring around-the-clock treatment over an extended period of time.

• Chronic Osteoarthritis Pain: The ER formulation provides sustained pain relief for patients with osteoarthritis of the knee and hip who require continuous analgesic therapy and have not achieved adequate relief with non-opioid analgesics.
• Chronic Lower Back Pain: Tramadol ER is effective for patients with chronic mechanical lower back pain requiring long-term opioid therapy, providing consistent pain control with once-daily dosing.
• Neuropathic Pain: The dual mechanism of tramadol, combining opioid agonism with serotonin-norepinephrine reuptake inhibition, provides benefit in certain neuropathic pain conditions such as diabetic peripheral neuropathy.
• Chronic Pain in Elderly Patients: The ER formulation is particularly useful in elderly patients who benefit from stable analgesic levels and once-daily dosing, though dose adjustments are required based on renal and hepatic function.

Why Manufacturers Choose Tramadol HCl ER

Tramadol hydrochloride extended-release 100 mg tablets are a specialized analgesic product manufactured by select Indian pharmaceutical companies with expertise in controlled-release formulations. The ER segment represents a value-added product category compared to immediate-release tramadol, commanding premium pricing.

WHO-GMP certified manufacturing facilities produce tramadol ER tablets using advanced release-controlling technologies. The product is in steady demand for chronic pain management in both domestic and export markets. Indian manufacturers supply tramadol ER tablets to regulated markets including the United States and Europe, where extended-release opioid analgesics have consistent demand. For PCD pharma franchise companies and third party manufacturing arrangements, tramadol ER represents a specialized product that differentiates the analgesic portfolio from standard immediate-release offerings.